European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against a marketing authorization for the drug’s use in early symptomatic Alzheimer’s disease.

“Today’s positive opinion by the CHMP marks an important step forward in offering a potentially new and differentiated treatment option for people living with this chronic and debilitating ...

PRINCETON, N.J., March 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

The Scientific Advisory Group (SAG) has been called in to assist the EMA’s CHMP human medicines committee ... for a SAG meeting is “a commonly used procedure for new treatments and new ...

It is the first time that the CHMP has reviewed a medicinal product for the EU market under a centralised procedure simultaneously with a medicinal product for non-EU countries under the ‘Eu ...

The Princeton, N.J., biopharmaceutical company said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected by June 2.

Social Security's new procedures will transform how Americans communicate with the SSA, authenticate their identities, and obtain payments starting on March 31. Wide-ranging modifications to ...

After a day of repeated denials in sworn testimony, top White House intelligence officials are back on Capitol Hill for a hearing on worldwide threats before House lawmakers on the intelligence ...

Sign up here to receive “The US in brief” as a newsletter, each weekday, in your inbox. The Trump administration reportedly plans to end funding for Gavi, an ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...

The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three biosimilars for approval at its March 2025 meeting. The committee recommended ...